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Abstract In this paper we demonstrate that the expression of 
the multidrug resistance-associated protein (MRP) in a variety of 
intact human tumour cells results in the ATP-dependent, 
mutually exclusive extrusion of both the acetoxymethyl ester 
and the free anion forms of the fluorescent dye calcein, as well as 
that of a fluorescent pyrenemaleimide-glutathione conjugate. 
The MRP-dependent transport of all these three model 
compounds closely correlates with the expression level of MRP 
and is cross-inhibited by hydrophobic anticancer drugs, by 
reversing agents for MDR1, and also by compounds not 
influencing MDR1, such as hydrophobic anions, alkylating 
agents, and inhibitors of organic anion transporters. Cellular 
glutathione depletion affects neither the MRP-dependent extru- 
sion of calcein AM or free calcein, nor its modulation by most 
hydrophobic or anionic compounds, although eliminating the 
cross-inhibitory effect of glutathione conjugates. These results 
suggest that the outward pumping of both hydrophobic 
uncharged and water-soluble anionic compounds, including 
glutathione conjugates, is an inherent property of MRP, and 
offer sensitive methods for the functional diagnostics of this 
transport protein as well as for the rapid screening of drug- 
resistance modulating agents. 
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1. Introduction 
A large number of clinically observed resistance of cancers 
t(  chemically unrelated cytotoxic ompounds i  caused by the 
o~ erexpression of multidrug transporter proteins in the tu- 
mour cell membranes. The two major multidrug transporter 
gone products identified are MDR1 (P-glycoprotein, P-170), 
arid MRP (multidrug resistance-associated protein, P-190), 
x~ rich are both members of the ATP binding cassette (ABC) 
tr msporter family, and perform an ATP-dependent extrusion 
ot various cytotoxic agents. Many of the transported com- 
p, mnds are of natural origin, and in the case of MDR1 they 
aJ e relatively large, hydrophobic, either uncharged or weakly 
b~sic molecules [1~1]. 
*t '.orresponding author. Fax: (36) (1) 185 2234. 
Ae,breviations. ADR, adriamycin (doxorubicin); AM, acetoxymethy- 
letter; CCCP, chlorocarbonyl cyanide phenylhydrazone; 2,4-DNP, 
2,4-dinitrophenol; DMEM, Dulbecco's modified Eagle's medium; 
FCS, fetal calf serum; GSH, reduced glutathione; MDR1, multidrug- 
resistance protein; MRP, multidrug resistance-associated protein; 
NEM, N-ethylmaleimide; NPM, N-pyrenemaleimide; PGA1, prosta- 
glandin A1 ; PVDF, polyvinylidene difluoride; VBL, vinblastine. 
MRP has recently been cloned [4] and its function as a 
drug-extrusion pump established [5,6], but the nature of the 
transported rugs and other chemicals is still controversial. 
According to several reports, MRP effectively pumps out 
most substrates of MDR1, but may also interact with a wider 
range of chemicals, and seems to be specifically modulated by 
genistein and probenecid [6-14]. MRP was shown to bind and 
transport glutathione S (GS) conjugates, such as leukotriene 
C4 [8-10], and other large anionic substances ([15]; P. Twenty- 
man, personal communication), thus raising the possible simi- 
larity or identity of MRP and the multispecific organic anion 
transporter (MOAT; [16]). Moreover, a recent communica- 
tion [17] suggested that the key mechanism of the cytotoxic 
drug resistance induced by MRP is the extrusion of intracel- 
lularly formed drug-GS conjugates. 
Earlier we have shown [18] that hydrophobic acetoxymethyl 
ester (AM) derivatives, but not the free acid forms of various 
fluorescent indicators, are actively extruded by the P-glyco- 
protein (MDR1), and that the measurement of the cellular 
accumulation of such an indicator, e.g. calcein, can be effec- 
tively utilised for the diagnostics and the transport character- 
ization of MDR1 [19,20]. Moreover, the rapid extrusion of 
calcein AM before its cleavage by cellular esterases suggested 
a drug-transport mechanism by MDR1 directly from the 
membrane phase. The experiments described in this paper 
demonstrate that calcein AM is also extruded by the human 
MRP, although in this case the hydrophilic free calcein anion, 
and an intracellularly formed fluorescent GS-pyrenemaleimide 
complex can also be exported. The studies presented here on 
the cross-inhibition of the transported compounds, as well as 
the effects of different drugs and of cellular glutathione deple- 
tion on the MRP-dependent transport, may significantly help 
our understanding of the molecular mechanism of this clini- 
cally important ransport pathway. 
2. Materials and methods 
2.1. Cell culturing 
Cell culturing was performed under standard conditions in RPMI 
or DMEM media, containing 10% fetal calf serum, 5 mM glutamine, 
100 U/ml penicillin, and 100 ktg/ml streptomycin. S1 (SW1573 cells), 
and S1MRP (MRP-transfected S1 cells re-selected and cloned in 
ADR-containing media), were originally prepared as described in 
[6]. GLC4, and GLC4 ADR (GLC4 cells selected in ADR and reg- 
ularly re-selected with 1 p.M ADR containing media) were described 
in [21]. These cell lines were kind gifts of Drs. P. Borst, A. Schinkel 
and G. Zaman, while HL60 ADR (ADR-selected HL60 cells) were 
gifts of Dr. M. Center (see [22]). K562 MDR1 (selected in ADR and 
regularly re-selected in 50 ng/ml ADR), were prepared in our labora- 
tory. KB3 and KB-VI (containing MDR1 and grown in media con- 
taining 50-500 ng/ml vincristine) human epidermoid carcinoma cells, 
NIH 3T3 fibroblasts and their human MDRl-transfected counterpart 
(NIH 3T3 MDR1 G185, see [23]) were kind gifts of Dr. M. M. 
Gottesman. Drug resistance was determined by cell counting after a 
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72 h incubation of the cells in 24-well plates in the respective culture 
media, supplemented with various concentrations of adriamycin. Ad- 
herent cells (NIH 3T3, S1, GLC4, KB, and KBV1 control and drug- 
resistant counterparts) were detached by mild trypsinization (5 min, 
1 mg/ml trypsin), then washed and resuspended in HPMI medium. 
2.2. Calcein fluorescence 
Calcein fluorescence was measured by incubating 2 5 × 10 ~ cells/ml 
in HPMI medium [18,24] containing 0.25 ktM calcein AM (Molecular 
Probes, Eugene, OR, USA), at 37°C with gentle stirring in a Hitachi 
F-4000 fluorescence spectrophotometer (excitation and emission wave- 
lengths for calcein were 493 and 515 nm, respectively, with a band 
width of 5 nm). No self-quenching of free calcein was observed under 
the experimental conditions used in the present experiments ( hort 
incubation periods and low concentrations of calcein AM in the in- 
cubation medium). The multidrug-resistance a tivity factor (MAF, see 
[20]) was calculated according to the equation: 
MAF = (F*-F)/F* (1) 
where F" and F designate the dye accumulation rate in the presence 
and absence of an inhibitor of the multidrug transporter, respectively. 
2.3. Inhibition of MRP-, or MDRl-dependent calcein AM extrusion 
Inhibition of MRP-, or MDRl-dependent calcein AM extrusion by 
various compounds was determined by measuring the rate of increase 
in fluorescence of free calcein for 5 min periods, and the ICs0 values 
were obtained by estimating the drug concentrations resulting in 50% 
of the maximum transport inhibition. Maximum inhibition was 
achieved in each experiment by the addition of 100 ~tM verapamil 
or 100 ~tM vinblastine, and the 100% range was calculated by sub- 
tracting the rate of fluorescence increase without any inhibitor from 
that at maximum inhibition. In each case the values represent the 
range obtained in at least 3 independent experiments with each cell 
line. 
2.4. A TP depletion 
ATP depletion was achieved by 1 h incubation of the cells at 37°C 
in HPMI media containing no glucose but 5 mM 2-deoxyglucose and 
5 mM NAN3, producing cellular ATP levels below 10% of the original 
[15]. 
2.5. GSH depletion 
GSH depletion was achieved by 24 h preincubation of the cells in 
the culture media supplemented with 50 txM butathione sulfoximine 
(BSO), or with a 5 min preincubation with 50 ktM diamide, followed 
by a washing in HPMI medium. Cellular GSH levels were examined 
by NPM fluorescence measurements (see below), and in both methods 
the non-protein SH levels were reduced to less than 10% of the ori- 
ginal (see also [12-14]). 
2.6. Quantitative immunoblotting 
Quantitative immunoblotting was performed by washing the cul- 
tured cells twice in a protein-free (HPMI) medium followed by dis- 
solution and sonication in a disaggregation buffer [24]. Detection of 
human MRP with the R1 (rat) monoclonal anti-MRP antibody, 
kindly provided by Dr. R. Schaper, was carried out as described in 
[25], while detection of MDR1 was performed with the 4077 anti- 
MDR1 polyclonal antibody on the same blots [18]. The second anti- 
bodies were obtained from Boehringer (anti-rat, peroxidase conju- 
gated IgG, 1000x dilution), and from Jackson Immunoresearch 
(anti-rabbit, peroxidase conjugated goat IgG, 20000× dilution). 
HRP-dependent luminescence on the blots (ECL, Amersham) was 
determined by autoradiography and by excising the respective bands 
from the PVDF membrane and measuring their luminescence in a 
liquid scintillation counter (Beckman LS 6000, Single Photon Monitor 
mode). 
2.7. NPM labelling 
NPM labelling of the cells was performed by incubating 5× 106 
cells in 1 ml HPMI medium in the presence of 0.5 ktM NPM for 
5 min at 4°C. The cell suspension was spun in an Eppendorf micro- 
centrifuge (20 s, 10000×g) and the pellet rapidly diluted in 5 ml of 
HPMI, prewarmed to 37°C. The concentration f unconjugated NPM 
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(the fluorescence of which is less than 10% of the S-conjugated mole- 
cule) after the loading procedure was determined by the addition of 
free glutathione to the loading medium, and was found to be negli- 
gible. Non-protein SH was determined by NPM titration of the super- 
natant of trichloroacetic acid-precipitated cells. 
2.8. NPM-S conjugate fftux measurements 
In the NPM-S conjugate fflux measurements, samples of the cell 
suspension, taken at the times indicated, were rapidly spun as above, 
and the supernatants were collected. The amount of total releasable 
NPM-S conjugate was determined by the addition of 1 mg/ml digito- 
nin to the cell suspension and by preparing a cell-free supernatant by 
rapid centrifugation, as described above (this was not significantly 
different from the amount of non-protein NPM-S conjugate, deter- 
mined after trichloroacetic a id precipitation of the cells). The fluores- 
cence of NPM-S conjugate was determined at excitation and emission 
wavelengths of 337 and 375 nm, respectively, with a band width of 20 
nm, in samples diluted 5 times with distilled water. The above fluor- 
escence measurement procedure minimised the possible ffects of en- 
ergy transfer due to the changing environment of the fluorophore. 
3. Results and discussion 
Calcein AM is non-fluorescent, and the fluorescence of free 
calcein, which is produced by esterases and then trapped in 
the cytoplasm of most living cells, is essentially insensitive to 
changes of pH, calcium, or magnesium concentrations [26]. As 
shown in Fig. 1A, when tumour cells were incubated in the 
presence of low concentrations (e.g. 0.25 ~tM) of calcein AM,  
and the increase of free calcein concentrat ion was followed by 
f luorometry in a stirred cuvette at 37°C, this increase was 
much slower in MRP-transfected SW1573/S1 lung cancer cells 
Table 1 
Inhibitors of the MRP-and/or MDRl-mediated calcein AM extru- 
sion 
Compound IC5o (~tM) 
MRP MDR1 
Vinblastine 2-5 2 3 
Tamoxifen 3-6 2 5 
Cyclosporine A 24 0.5-1 
Verapamil 4~8 2-5 
Econazole 3 10 1-3 
Quinine 50-100 20-30 
Oligomycin 1 2 1-2 
CCCP 10-30 >200 a
2,4-DNP 30-50 >200 a
Probenecid 500-800 >2000 a 
Sulfinpyrazone 300-500 >2000 a 
Benzbromarone 5-10 > 500 ~,b 
Indomethacin 1 0-20 > 800 a,b 
Na-cholate 200-300 > 1000 b
Bromosulfophthalein 100-150 > 1000 b
Ethacrynic acid 2(~30 >800 b
Merthiolate 1 0-20 >200 b
NEM 0.24).5 >50 b 
NPM 0.1~.2 >20 b 
Genistein 150-200 b > 1000 ~,b 
Chlorambucil 30-50 > 500 b 
Prostaglandin Aa 3 5 > 100 ~ 
Drug effects on MRP were estimated from calcein accumulation 
measurements in S1MRP and in HL60 ADR cells, while the effects 
on MDR1 were deduced from similar measurements in 3T3 MDR 
and K562 MDR cells. In each case the values represent the range 
obtained in at least 3 independent experiments with each cell line. 
> indicates that 50% inhibition could not be achieved in the mea- 
surable concentration range, and either a solubility problem (a), or 
a strong esterase inhibition (b) was experienced at higher concentra- 
tions. 
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than in untransfected control cells. Since in the MRP-trans- 
fected cells the rate of calcein production was greatly in- 
creased (up to the rates seen in the control cells) by ATP 
depletion, or by the addition of vinblastine or verapamil, 
the slower calcein production was not due to reduced cellular 
eslerase activity, but to active, MRP-dependent elimination of 
A 
?: 
S~ ceils SIMRP cells ATP-depleted S1MRP cells 
t t t t t t 
CaAM VBL CaAM VBL CaAM VBL 
2 rain 
B 
K562 MDR1 cells S1MRP cells 
t t t t t t 
CaAM NPld Verapamil CaAM NPM Verapamil 
2 min 
C 
GSH depleted S1MRP cells (BSO pretreatment) 
t t t t t t 
CaAM NPM VBL CaAM PGA 1 VBL 
D 
o 
,T 
GSH depleted S1MRP cells (diamide pretreatment) 
t t t t t t 
CaAM VBL NPM CaAM NPM VBL 
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calcein AM from tumour cells. A similar strong reduction of 
free calcein production, and its reversal by ATP depletion, 
verapamil or vinblastine was observed in HL60 ADR and in 
GLC4 ADR multidrug-resistant tumour cells, all of which 
express MRP but not MDR1 (see below). 
In these fluorometry experiments he conversion of calcein 
AM to free calcein was measured, thus MRP most probably 
extrudes the hydrophobic calcein AM before its esterase cleav- 
age. These findings indicate a similar drug transport mechan- 
ism to that seen in the case of MDR1 [18]. In order to clarify 
the possible role of MDR1 in the observed phenomena, the 
cell extracts were subjected to immunoblotting with specific 
monoclonal antibodies. As shown in Fig. 2, MRP-expressing 
cell lines had no detectable l vels of MDR1, and MDRI-ex- 
pressing cells did not show increased MRP expression (a very 
low level of MRP could be detected even in most of the 
parental cell lines as well). Moreover, the differences in calcein 
accumulation rates in the absence and presence of vinblastine, 
respectively (shown as the multidrug-resistance a tivity factor, 
MAF), as well as the drug resistance of these different cell 
lines, closely correlated with the relative amounts of the re- 
spective multidrug-resistance proteins (Fig. 2). 
In the following experiments we have compared the mod- 
ulation of the MRP-dependent and MDRl-dependent calcein 
AM extrusion, respectively, by several pharmacologically ac- 
tive compounds. Acceleration of cellular calcein production to 
the control level, i.e. inhibition of calcein AM extrusion, was 
produced in the S1MRP and HL60 ADR cells by several 
unrelated compounds, acting with the respective apparent 
IC50 values as listed in Table 1. The inhibitory effects of all 
these compounds on calcein extrusion were found to be simi- 
lar in GLC4 ADR cells as well, although in this case the 
respective IC50 values were generally about 50% higher than 
in the two other MRP-expressing cell types. As shown in 
Table 1, some of these compounds (e.g. vinblastine, tamoxi- 
fen, verapamil, cyclosporin A, quinine, or econazole) inhibited 
calcein AM extrusion from MRP or MDRl-expressing cells 
with almost the same efficiency. However, several molecules, 
such as the hydrophobic anions CCCP, 2,4-DNP; weak acids 
modulating uric acid or bile acid transport (e.g. probenecid, 
sulfinpyrazone, benzbromarone, bromosulfophthalein, etha- 
crynic acid, indomethacin, cholic acid); alkylating agents 
(e.g. chlorambucil), cell-permeant mercury or maleimide 
derivatives (e.g. merthiolate, NEM and NPM; see Fig. 1B), 
as well as prostaglandin A1, but not E1 or F2a, selectively 
inhibited MRP-dependent dye extrusion. Although some of 
these compounds during longer incubations may induce cel- 
lular ATP depletion or a non-specific increase in membrane 
permeability, during the measurement periods of 10-15 min 
the applied concentrations had no such effects, as shown by 
<.__ 
Fig. 1. Production of free calcein in drug-sensitive and drug-resist- 
ant cells: effects of glutathione depletion. Drug-sensitive (S1) and 
drug-resistant (S1MRP and K562 MDR1) cells were incubated in 
the presence of 0.25 ~tM calcein-AM, and at the times indicated by 
the arrows the respective agents were added to the media. The plots 
show calcein fluorescence (in arbitrary units) against ime. (A) S1, 
S1MRP and ATP-depleted S1MRP cells; (B) K562 MDR1 and 
S1MRP cells; (C) S1MRP cells depleted from GSH by 24 h BSO 
pretreatment; (D) S1MRP cells depleted from GSH by pretreatment 
with diamide. Additions: CaAM = 0.25 ~M calcein AM; VBL = 10 
ktM vinblastine, verapamil = 100 laM; NPM = 1 ~tM N-pyrenemalei- 
mide. 
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Fig. 2. Estimation of MRP and MDR1 expression by immunoblot- 
ting in various cell lines, and characteristics of their calcein extru- 
sion rate and ADR resistance. (A) Immunoblot detection of human 
MRP by the R1 anti-MRP monoclonal antibody; (B) detection of 
MDR1 protein by the polyclonal antibody, 4077. Each lane con- 
tained 20 rtg cellular protein. Lanes: 1A, S1 control cells; 1B, 
S1MRP cells; 1C, S1MRP cells with ADR selection; 2A, HL60 
control cells; 2B, HL60 ADR cells; 3A, GLC4 control cells; 3B, 
GLC4 ADR cells; 4A, K562 control cells; 4B, K562 MDR1 cells. 
For the calculation of the multidrug-transporter activity factor 
(MAF), and the measurement of adriamycin resistance see section 2. 
the lack of modulation of calcein AM extrusion m MDR1- 
expressing cells (Fig. 1B). 
Since the formation of drug-GS conjugates was suggested 
as the key mechanism for MRP-dependent drug extrusion 
[11-15,27], in the following experiments we have examined 
the effects of cellular glutathione (GSH) depletion on MRP- 
dependent calcein AM efflux. In S1MRP or HL60 ADR cells 
GSH depletion, achieved either in a 24 h preincubation with 
50 ~tM BSO (a specific inhibitor of glutathione synthetase, see 
[11-15,27]), as shown in Fig. 1C, or in a 5 min preincubation 
with 50 ~tM diamide (a selective glutathione oxidising agent; 
see [28]), followed by washing of the cells in a medium with- 
out amino acids (Fig. 1D), did not significantly affect calcein 
AM extrusion, or its inhibition by vinblastine. This was true 
for many other agents, e.g. verapamil, cyclosporine A, PGA1 
(see Fig. 1C), or probenecid. In contrast, the inhibition of the 
MRP-dependent calcein AM extrusion by micromolar con- 
centrations of the hydrophobic SH-reactive agents, N-ethyl- 
maleimide (NEM) and N-pyrenemaleimide (NPM; see Table 
1) was eliminated by GSH depletion (Fig. 1C,D). It should be 
mentioned that the addition of 50 ~tM BSO or diamide to the 
calcein AM uptake assay induced a slight increase in free 
calcein production, thus these compounds may (partially) di- 
rectly inhibit MRP-dependent drug transport. 
In the calcein AM transport experiments we noted that 
NEM or NPM inhibition of free calcein formation was fully 
reversible upon 5 10 min incubation of the cells at 37°C, in 
spite of the irreversible reaction of these agents with SH 
groups. The S-conjugates of NPM show a characteristic fluor- 
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escence mission, thus the complex formation and transport 
of this molecule in the tumour cells could be directly exam- 
ined. The NPM fluorescence measurements ( ee section 2) 
showed that this maleimide derivative, when added in submi- 
cromolar concentrations to the medium, rapidly diffused into 
the cells and formed predominantly non-protein S-, thus 
mostly GS-conjugates. As shown in Fig. 3 for HL60 cells, in 
contrast o the parental non-resistant cells, MRP-containing 
tumour cells exhibited rapid extrusion of the intracellularly 
formed, water-soluble GS-NPM complex, and this extrusion 
was inhibited by low concentrations of calcein AM, vinblas- 
tine, or PGA1. The same results were obtained with S1 and 
S1MRP cells, respectively, i.e. rapid GS-NPM efflux was only 
observed in the MRP-expressing cell, while the MDRl-expres- 
sing K562 cells did not show such GS-NPM extrusion. In 
both HL60 MRP and S1MRP cells the rapid phase of GS- 
NPM efflux was inhibited by verapamil, quinine, or probene- 
cid, and also eliminated by ATP depletion (data not shown). 
The above experiments indicate that intracellular GS con- 
jugates are transported substrates of MRP, although, as 
shown above, the interaction of MRP with several trans- 
ported molecules does not seem to involve GS-conjugate for- 
mation. Still, GS conjugates inhibit calcein AM extrusion and 
calcein AM inhibits GS-NPM conjugate transport, while both 
of these transports are similarly affected by all the different 
MRP-modulating compounds. 
In most living cells, including MDRl-expressing tumour 
cells, free calcein is trapped and is not significantly released 
[18,26]. However, a recent report indicated relatively rapid, 
ATP-dependent effiux of the accumulated free calcein from 
MRP-expressing cells [15]. Indeed, when measuring the effiux 
of free calcein from the S1 MRP and HL60 ADR cells, in 
contrast o that seen in the MDRl-expressing fibroblasts or 
K562 tumour cells, we also observed increased calcein efflux, 
blocked by low concentrations of verapamil, vinblastine, pros- 
taglandin A1, NEM, NPM, and by all the agents inhibiting 
calcein AM extrusion (as listed in Table 1). In accordance 
with the results in [15], in our experiments GSH depletion 
by BSO did not modify the MRP-dependent free calcein efflux 
either. The rates of free calcein extrusion in the different cell 
types correlated well with the expressed amounts of MRP: the 
time required for a 50% decrease of cellular free calcein (at an 901 l e  80 
.~" 70 
~ 60 
50- 
03 
(.:3 
~ 40. 
O. 
z 30- 
201 
10 • --4,'-- HL60 MRP + CaAM 
g 1'0 l's 2'0 
Time (rain) 
Fig. 3. Ettlux of water-soluble NPM-S conjugate from HL60 tumour 
cells. (©) HL60 control cells; (e) HL60 ADR cells; ( - )  HL60 
ADR cells+100 ~tM vinblastine; (v) HL60 ADR cells + 10 ~tM 
PGA1; (0) HL60 ADR cells + 0.5 ~tM calcein AM. 
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initial value of about 1 mM) was more than 60 min in S1MRP 
cells, 25 min in ADR-selected S1MRP cells and 20 min in HL 
60 ADR cells. An important point in these experiments is that 
relatively high intracellular f ee calcein concentrations (0.5-2 
mM, achieved by preincubating the cells for 10 min in media 
containing 1-5 ~tM calcein AM) were required for a full stim- 
ulzttion of the free dye efflux by MRP, while submicromolar 
concentrations of calcein AM already produced efficient 
MRP-dependent extrusion (see Fig. 1). These observations 
re~der it unlikely that the MRP-dependent transport of any 
nc~ n-fluorescent, partially hydrolysed (thus negatively charged) 
fo m of calcein AM may significantly contribute to the ob- 
se~ ved calcein AM extrusion. 
Based on the above experimental data, we suggest hat 
M RP has an inherent ransport activity for a variety of chem- 
ic~dly and pharmacologically unrelated compounds, e.g. un- 
charged hydrophobic molecules, lipid-soluble anions, and hy- 
dr,)philic anions, including glutathione conjugates with 
maltiple and fully dissociating negative charges. The hydro- 
pt~obic substrates most probably do not have to be converted 
ino  GS conjugates, but seem to be recognised by MRP near 
to or in the hydrophobic membrane phase, as suggested for 
M DR1. This versatility makes MRP a highly efficient xeno- 
bi,)tic efflux pump, although the large differences in the ap- 
p~rent IC50 values for the different chemicals till indicate a 
liraited substrate acceptance. The specificity of the transporter 
is clearly shown by the relatively small transport effect of the 
in~ racellularly formed GS-SG complex (obtained in millimolar 
le"els during GSH depletion by diamide), or the selective in- 
hi!~ition of the MRP-dependent calcein movements by PGA1, 
al~d not by several other closely related prostaglandins. An 
earlier report [29], by studying multidrug resistance in L1210 
m,)use leukaemia cell line, demonstrated a pattern of shared 
st, bstrates and inhibitors closely resembling that shown in the 
plesent paper (including verapamil, quinidine, cholate, and 
pJ ostaglandin A1). 
An interesting observation i  these experiments i  the close 
ct,rrelation of the MRP-inhibitory effects with the pharmaco- 
logical effectivity of several agents (probenecid, sulfinpyrazone 
al:d benzbromarone) in blocking the active reabsorption of 
u~ ic acid in the human kidney [30]. This finding and the effects 
o1 other agents, e.g. indomethacin and bromosulfophthalein, 
o l  the MRP-dependent drug transport further support the 
p,,ssible molecular similarity or identity of MRP with the 
maltispecific organic anion transporter (MOAT; see [16]), 
p~ esent in various secretory epithelia. 
In this report we demonstrate hat the measurement of the 
f( rmation of free calcein from calcein AM in the tumour cells 
is especially suitable for characterizing the transport activity 
o~ MRP (in flow cytometry the additive ffects of calcein AM 
a ld  free calcein extrusion may occur), and by using appro- 
priate inhibitors, the function of MDR1 and MRP can be 
differentiated. This method has several advantages over other 
fl~lorescent dye (e.g. rhodamine 123 [31], or free calcein [15]) 
el:iux measurements, due to the steady-state conditions for 
czdcein AM transport, and the high-level accumulation of 
fr,ze calcein (see [20]). Both the calcein accumulation and 
flqorescent GS-NPM conjugate transport measurements are 
ai~o applicable for screening the MRP-inhibitory effects of 
wtrious compounds, as well as for determining the involve- 
ment of intracellular glutathione conjugation in the MRP-de- 
pendent ransport of a given molecule. 
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